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https://doi.org/10.1002/bmc.4290Abstract
A simple and specific UPLC–MS/MS method was developed and validated for simulta-
neous quantification of fentanyl, sufentanil, cefazolin, doxapram and its active metabo-
lite keto‐doxapram. The internal standard was fentanyl‐d5 for all analytes.
Chromatographic separation was achieved with a reversed‐phase Acquity UPLC HSS
T3 column with a run‐time of only 5.0min per injected sample. Gradient elution was
performed with a mobile phase consisting of ammonium acetate or formic acid in
Milli‐Q ultrapure water or in methanol with a total flow rate of 0.4mLmin−1. A plasma
volume of only 50μL was required to achieve adequate accuracy and precision. Calibra-
tion curves of all five analytes were linear. All analytes were stable for at least 48h in
the autosampler. The method was validated according to US Food and Drug Adminis-
tration guidelines. This method allows quantification of fentanyl, sufentanil, cefazolin,
doxapram and keto‐doxapram, which is useful for research as well as therapeutic drug
monitoring, if applicable. The strength of this method is the combination of a small sam-
ple volume, a short run‐time, a deuterated internal standard, an easy sample preparation
method and the ability to simultaneously quantify all analytes in one run.
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One of the most important issues in peri‐operative and intensive care
medicine is the establishment of an individual antibiotic and
analgosedation drug profile for each patient with respect to the clinical
situation, together with support of vital functions. In general, the anal-
gesic and sedation dose regime will be adjusted to the clinical situation
of each individual patient to shorten the duration of therapy and to
reduce morbidity (Chanques et al., 2006). Large knowledge gaps exist
with respect to the optimal drug therapy and covariates that- - - - - - - - - - - - - - - - - - - - - - - - - - -
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and well‐designed trials are required (Coppini et al., 2016).
For certain drugs therapeutic drug monitoring (TDM) has been
proven valuable for monitoring of drug effects, dosage regimes and
physiological changes, and when appropriate, adapting the medical
care to each patient in the intensive care unit. Despite the fact that
many drugs are still being dosed on clinical response, the continuously
expanding assortment of analytical methods improves drug safety and
individual patient treatment (Touw et al., 2005). For research as well
as for TDM, more assays are neeeded with a minimal sample volume,
a short run time, quick and easy sample preparation, and simultaneous- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 of 8 FLINT ET AL.measurement of multiple analytes. Simultaneous quantification in one
assay allows quantification of multiple analytes in one sample without
requiring extra sample volume, and allows to samples to be run con-
taining different drugs efficiently in one assay‐run.
Evidence is sparse on the use of fentanyl, sufentanil, cefazolin and
doxapram for certain pediatric age‐ranges and indications. Sufentanil,
fentanyl and cefazolin are part of peri‐operative treatments for chil-
dren. Furthermore, sufentanil and fentanyl are synthetic opioid analge-
sics widely used in clinical anesthesia and analgesia (Mather, 1983;
Pacifici, 2015). Cefazolin is a first‐generation cephalosporin beta‐lac-
tam antibiotic used for treatment of sepsis or life‐threatening infec-
tions (McWhinney et al., 2010), where adequate individual dosing
may be lifesaving. Doxapram has not been investigated sufficiently
in children, despite its frequent and promising use in neonatal inten-
sive care for treatment of apnea of prematurity (Flint et al., 2017, Flint
et al., 2017; Pacifici, 2015; Prins et al., 2013).
This assay will aid future research to close the knowledge gaps on
these four drugs, but may also be used for TDM if a target concentration
range can be defined. As these four drugs are commonly prescribed and
combined, we aimed to develop and validate a quick and easy analytical
method for simultaneous quantification of fentanyl, sufentanil, cefazolin,
doxapram and its active metabolite keto‐doxapram in human plasma by
ultra‐performance liquid chromatography–electrospray ionization–tandem
mass spectrometry (UPLC–MS/MS). We optimized the sensitivity of the
assay so to minimize the required sample volume, which allows measure-
ment of small volume samples, even from premature born infants.2 | MATERIALS AND METHODS
2.1 | Chemicals and reagents
Fentanyl, fentanyl‐d5 and sufentanil were purchased from Sigma Aldrich
(Zwijndrecht, the Netherlands). Cefazolin was obtained from Santa Cruz
Biotechnology (Heidelberg, Germany), doxapram from Selleckchem
(Munich, Germany) and keto‐doxapram from Tractus (London, UK).
Ammonium acetate was obtained from Sigma Aldrich (Zwijndrecht, the
Netherlands). Methanol, acetonitrile and formic acid were purchased from
Biosolve BV (Valkenswaard, the Netherlands). All reagents were LC–MS
grade, which means at least 99% purity. Water was purified by using a
MilliPore Advantage A10 system. Human drug‐free plasma was obtained
from the blood donation center (Sanquin, Rotterdam, the Netherlands).
2.2 | Stock solutions, calibration standards, quality
control samples and internal standard
Stock solutions of doxapram and keto‐doxapram were prepared at a con-
centration of 500mgL−1 using methanol. The following substance stock
concentrations in methanol were prepared: sufentanil at a concentration
of 20mg L−1; fentanyl at a concentration of 2mg L−1; and cefazolin at a
concentration of 5,000mg L−1 using Milli‐Q water. For each analyte
two separate stock solutions were made with the same concentration,
for calibration of standard samples and for quality control samples. Stock
solutions were stored at −20°C, except the stock solution of cefazolin
which was stored at 2–8°C. The calibration standard 8 and quality con-
trol (QC) high were made from the stock solutions with drug‐free humanplasma. Calibration standards 1–7 and the lower limit of quantification
(LLOQ) standard were prepared by serial dilution of calibration standard
8 with human plasma. QC medium and QC high samples were prepared
the same way, using the other stock solution (QC high), which was
diluted with human plasma. The concentrations of all calibration stan-
dards are given in Table 1 and the concentrations of the quality controls
are given in Table 2. Calibration standards and quality control samples
were stored as 50μL portions in 1.5mL Eppendorf tubes at −80°C prior
to analysis. The internal standard was fentanyl‐d5, which was dissolved
in a mixture of acetonitrile and methanol 1:1 at a concentration of
10μg L−1. The internal standard working solution was stored at −20°C.
2.3 | Sample preparation
A mixture of acetonitrile and methanol, containing 10 μg L−1 fentanyl‐d5
(the internal standard solution), was used for protein precipitation. A
50 μL aliquot of the calibration standards, quality control samples, blanks
and patient samples were thawed at least half an hour prior to prepara-
tion. Then plasma proteins were precipitated by adding 200μL of the
internal standard solution. Subsequently, the samples were vortexed
for about 10 s. After vortexing, the precipitant was separated by centri-
fugation for 5min at 16,000 g. A 100μL aliquot of each supernatant
was transferred into an autosampler insert vial (VWR, Amsterdam, the
Netherlands) and diluted by adding 400μL of mobile phase A. The
autosampler vials were mixed using the vortex for 10 s. For cefazolin,
doxapram and keto‐doxapram 1μL was injected into the UPLC. For fen-
tanyl and sufentanil, 10μL was injected into the system because of the
lower therapeutic range of these compounds (see Table 2).
2.4 | Instrumentation
A Dionex Ultimate UPLC system consisting of an Ultimate 3,000 RS
UPLC pump, an Ultimate 3,000 RS autosampler and an Ultimate
3,000 RS Column Compartment was used as the equipment. The UPLC
was connected to a Thermo TSQ Vantage triple quadrupole MS with
HESI probe (Thermo Scientific, Waltman, MA, USA). The software pro-
grams Chromeleon (version 6.8, Dionex, Thermo Scientific), Xcalibur
(version 2.1, Thermo Scientific) and LCquan (version 2.6, Thermo Sci-
entific) were used to control the system and analyze the data.
2.5 | UPLC conditions
Chromatographic separation, based on affinity of the analytes with the
nonpolar stationary phase, was achieved with a reversed‐phase UPLC
Acquity BEH C18 column, 1.7 μm, 2.1 × 100mm (Waters, Milford,
USA). Gradient elution was performed with a mobile phase consisting
of 1mL of a 154mg/L solution of ammonium acetate in formic acid
(99%) in 1 L of Milli‐Q ultrapure water (eluent A) and 1mL of the same
solution in 1 L of methanol (eluent B). Before the analysis, the system
was equilibrated at the starting conditions of 75% eluent A and 25%
eluent B until pressure was stable. The multistep gradient was as fol-
lows: from 0 to 0.6min, eluent B was increased from 25 to 48%; from
0.6 to 1.5min, eluent A decreased to 35% and B was increased to
65%; from 1.6 to 2.8min, eluent B was kept stable at 100% and 0%
eluent A; from 3.0 to 5.0min, eluent A was inceased to 75% and B
was decreased to 25%. The run ended at 5.0min at starting
TABLE 1 Concentrations of all calibration standards and lower limit of quantitation (LLOQ) standard
Analyte LLOQ (μg L−1) S1 (μg L−1) S2 (μg L−1) S3 (μg L−1) S4 (μg L−1) S5 (μg L−1) S6 (μg L−1) S7 (μg L−1) S8 (μg L−1)
Fentanyl 0.10 0.10 0.50 1.0 2.5 4.0 5.0 8.0 10
Sufentanil 0.25 1.0 5.0 10 25 40 50 80 100
Cefazolin 1,000 1,000 5,000 10,000 25,000 75,000 80,000 90,000 100,000
Doxapram 50 100 500 1,000 2,500 4,000 5,000 8,000 10,000
Keto‐doxapram 50 50 100 250 500 1,000 2,000 4,000 5,000
S, Calibration standard.
TABLE 2 Concentrations of all quality controls
Analyte
QC low
(μg L−1)
QC medium
(μg L−1)
QC high
(μg L−1)
Fentanyl 0.5 2.5 7.5
Sufentanil 2.0 10 30
Cefazolin 4,000 25,000 70,000
Doxapram 400 2,500 7,000
Keto‐doxapram 150 850 3,000
QC, Quality control.
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the autosampler at 15°C.
The separation was performed by gradient elution using mobile
phase A (1mL of 2 M ammonium acetate in formic acid 99%), in 1 L
Milli‐Q water and mobile phase B (1mL of 2 M ammonium acetate in
formic acid 99%), in 1 L methanol with a total flow rate of
0.4mLmin−1. Mobile phase B was kept at 25% from 0.0 to 0.6min,
then at 48%, from 0.6 to 1.5min mobile phase B at 65%, then from
1.6 to 2.8min at 100%, from 3.0 to 5.0min mobile phase B was kept
at 25%. The run ended at 5.0min at starting conditions. Temperature
for the column oven was set at 50°C and for the autosampler at 15°C.2.6 | MS/MS conditions
MS/MS detection was performed in positive mode using selected
reaction monitoring (SRM) with electrospray ionization. To optimize
the MS/MS parameters to detect the most intense signal of each ana-
lyte, solutions of 1mg L−1 were directly infused in methanol by addi-
tion of the mobile phase (75% mobile phase A and 25% mobile
phase B) from the LC at a flow rate of 0.4mLmin−1. The MS/MS
instrument was operated with a capillary spray voltage of 3 kV, vapor-
izer temperature at 375°C, capillary temperature at 250°C, sheath gas
pressure at 50 (arbitrary units), auxiliary nitrogen gas pressure at 20
(arbitrary units) and collision gas pressure at 1.5 mTorr. Specific param-
eters for each compound are given in Table 3.TABLE 3 MS/MS settings
Analyte
Parent ion
(m/z)
Product ion
(m/z)
Collision
energy (V)
S‐Lens
(V)
Fentanyl 337.4 188.2 22 124
Fentanyl‐d5 342.4 188.2 22 124
Sufentanil 387.3 238.2 18 124
Cefazolin 455.1 323.0 10 80
Doxapram 379.3 128.1 55 135
Keto‐doxapram 393.2 214.1 26 1502.7 | Assay validation
Validation of the method was performed according to the US Food
and Drug Administration (2003) guidelines for bioanalytical methods.
The following validation parameters were investigated: linearity, LLOQ
and upper limit of quantification (ULOQ), accuracy, repeatability,
reproducibility, stability and matrix effect.
2.7.1 | Linearity
To investigate the linearity of the method, a blank sample (without
internal standard), a zero sample (blank with internal standard) and
eight calibration standards in duplicate were prepared and analyzed.
Calibration curves were generated by plotting the theoretical standard
concentration vs the ratio of the standard peak area to the internal
standard area. The determination coefficient (R2) should be at least
0.9950. The relative standard deviation (RSD) of the calculated con-
centrations of the standard concentrations was required to be <15%,
except at the LLOQ, where it should not deviate by more than 20%.
It was decided to apply weighting 1/x, which means that standards
with the lowest concentrations are more important for the calibration
line than standards with highest concentrations (Saar et al., 2010). The
calibration curves were formed using the peak area ratios for the
analytes and their corresponding internal standard (response) vs the
concentrations applying linear least square regression with a weighing
factor of 1/x and excluding of the origin.
2.7.2 | LLOQ and ULOQ
The LLOQ was measured by analyzing the LLOQ standard six times in
a row. Mean and standard deviation of the response ratios of the six
samples were measured. The response of the analyte should be at
least 5 times the response compared with the response of the blank.
Precision and accuracy were calculated and should be ≤20% and the
accuracy should be between 80 and 120%. The highest standard of
the calibration curve was used as the ULOQ.
2.7.3 | Accuracy
Accuracy was measured by measuring three concentrations (QC‐H,
QC‐M and QC‐L) six times on the same day. The percentage differ-
ence between the measured concentration and the theoretical con-
centration, known as the relative standard deviation (RSD), was
required to be <15%.
2.7.4 | Repeatability and reproducibility
The repeatability was tested by analyzing three QC levels six times on
the same day. The reproducibility was tested by analyzing three
4 of 8 FLINT ET AL.concentrations in duplicate on six different days. The requirement for
both parameters was an RSD <15%.
2.7.5 | Stability
Autosampler stability was determined by storing QC samples (n = 2 per
concentration) after sample preparation in the autosampler for 24, 48,
72 and 120 h. Response ratios were measured and compared with
response ratios of samples kept at −80°C prior to preparation. After
sample preparation, samples were directly analyzed. Recovery was
required to be between 90 and 110%.
2.7.6 | Matrix effect
It is important to measure matrix effects and absolute recoveries in
the development of an LC–MS/MS method since ion suppression
and ion enhancement effects can be expected owing to interferences
by matrix compounds, stable‐isotope‐labeled internal standards and
co‐eluting compounds (Van Eeckhaut et al., 2009). In order to check
whether the precision, the reproducibility and the stability of the con-
centration‐signal ratio are affected by interference of the matrix
analytes, the method described by Matuszewski et al. (2003) was
used. Five different lots of human plasma were used. To two concen-
tration levels (QC low and QC high, both in duplicate), the analytes
were added before and after extraction, which served to calculate
the recovery. Also, a set of six academic samples was evaluated with
only Milli‐Q ultrapure water instead of plasma. Matrix effects were
calculated as follows:
peak area of analyte spiked after extraction/peak area of analyte
prepared in Milli‐Q ultrapure water × 100%.
The process efficiency was calculated as the percentage ratio of
the area of the analytes spiked before extraction and the ones pre-
pared in Milli‐Q ultrapure water. The mean and RSD were calculated
of matrix effects, process efficiency and recovery. In the ideal situa-
tion, the mean matrix effects, process efficiency and recovery are
between 80 and 120%, and the RSD of both parameters is ≤15%. Fur-
thermore, for each analyte, the internal standard normalized matrix
effect should also be calculated by dividing the matrix effect of the
analyte by the matrix effect of the IS. The RSD of the internal stan-
dard‐normalized matrix effect calculated from the different lots of
matrix should not be greater than 15%.2.8 | Clinical application
The method was developed for the analysis of plasma samples from a
pharmacokinetic study and may also be used for TDM, if this can be
proven clinically valuable. For the validation of the assay for clinical
practice, clinical application and research purposes the method was
applied to quantify doxapram, keto‐doxapram and fentanyl in plasma
of preterm infants participating in a clinical study. The Erasmus
Medical Center ethics review board approved the protocol and
written informed consent from parents/legal guardians was obtained
prior to study initiation (MEC‐2014‐067, ClinicalTrials.gov by
NCT02421068). This observational prospective multicenter study
was performed between September 2014 and June 2017 at the
Departments of Neonatology of the Radboud University Medical Cen-
tre in Nijmegen, Maastricht University Medical Centre in Maastricht,Maxima Medical Centre in Veldhoven and Sophia Children's Hospital
in Rotterdam. Neonates routinely received doxapram (Dopram®,
Manage, Belgium) for treatment of apnea of prematurity starting with
a loading dose of 2.5mg kg−1 bodyweight in 15min, followed by a
maintenance starting dose of 2.0mg kg−1 h−1, either by continuous
intravenous infusion or continuous gastro‐enteral administration. Fen-
tanyl (Bipharma, Almere, the Netherlands) was indicated for comfort
as an intravenous continuous infusion of 0.5–2.0 μg kg−1 h−1 or as a
bolus injection of 0.5–3.0 μg kg−1.3 | RESULTS
3.1 | Linearity
Linearity was achieved for each analyte in the range between the
LLOQ and the ULOQ (Table 2), with all RSDs to be <15% and the
determination coefficient (r2) to be at least 0.995. The calibration
curves showed that a regression with a weighting factor of 1/x best
described the dataset over the range for all analytes. Figure 1 shows
the ion chromatograms obtained after the analysis of the lowest
plasma calibrator standard for all the analytes, and the corresponding
retention times of each analyte (see Table 1).3.2 | LLOQ and ULOQ
The results for the LLOQ for cefazolin, keto‐doxapram and fentanyl
did not meet the initial requirements. Therefore, the LLOQ for these
analytes was set to calibration standard 1, which was acceptable.
The results of determination of LLOQ and ULOQ are shown in
Table 4.3.3 | Accuracy, repeatability and reproducibility
The RSD of accuracy, repeatability and reproducibility data were
within the requirement of an RSD <15% (Table 4).3.4 | Stability
Except for cefazolin and keto‐doxapram, the recovery of all QCs was
between 90 and 110%, indicating that they were stable for at least
120 h when stored in the autosampler at 15°C. Cefazolin was only sta-
ble for 72 h and keto‐doxapram only for 48 h.3.5 | Matrix effect
Matrix effects and absolute recoveries in the development of the LC–
MS/MS method are shown in Table 5. The method described by
Matuszewski et al. (2003) showed that fentanyl, sufentanil, cefazolin,
doxapram and keto‐doxapram experienced neither matrix effect nor
an effect from the sample preparation. A good recovery was achieved
for all analytes.3.6 | Clinical application
A total of 618 samples were collected from a pediatric cohort of pre-
term infants (n = 157), consisting of 92 infants who received fentanyl
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FIGURE 1 Ion chromatograms of all analytes and internal standard in lowest concentration calibration standard 1 (see Table 1). For the ion
chromatograms of sufentanil and fentanyl, 10 μL was injected, and for cefazolin, doxapram and keto‐doxapram the injection volume was 1 μL.
RT, Retention time; AA, automatic integrated area
FLINT ET AL. 5 of 8and 65 infants with doxapram. Eleven samples were collected from six
patients from the cohort of 157 infants who received fentanyl and
doxapram simultaneously. The median gestational age of the fentanyl
cohort was 27.1weeks (range 24.3–31.2weeks), median postnatal age
at start of drug therapy was 4.5 days (range 0–68 days) and median
body weight at start of drug therapy was 968 g (range 465–3,000 g).
The median gestational age of the doxapram cohort was 26.1weeks
(range 24.0–29.4weeks), median postnatal age at start of drug ther-
apy was 17 days (range 1–52 days) and median body weight at start
of drug therapy was 960 g (range 650–1,520 g).
Fentanyl was quantified in 370 samples from 92 patients, and
doxapram and keto‐doxapram in 248 samples from 65 patients. For
fentanyl, 78 (21%) of the 370 samples were measured below theLLOQ, and 19 (5%) below the LOD. For doxapram 29 (12%) and for
keto‐doxapram, 33 (13%) of the 248 samples were below the LLOQ,
and eight (3%) doxapram and six (2%) keto‐doxapram measurements
were below the LOD. For doxapram, three (1.2%) samples were mea-
sured above the ULOQ.4 | DISCUSSION
We developed a robust UPLC–MS method for simultaneous quantifi-
cation of fentanyl, sufentanil, cefazolin, doxapram and its active
metabolite keto‐doxapram according to US Food and Drug Adminis-
tration guidelines. The easy sample preparation, small required sample
TABLE 4 Validation results (n = 6)
Analyte QC Accuracy, RSD (%)
Repeatability (within‐run precision) Reproducibility (between‐run precision)
LLOQ ULOQ
Mean (μg L−1) SD (μg L−1) RSD (%) Mean (μg L−1) SD (μg L−1) RSD (%) (μg L−1) (μg L−1)
Fentanyl L −2.7 0.46 0.01 1.5 0.51 0.02 3.9 0.10 10.0
M −2.7 2.1 0.05 2.4 2.00 0.03 1.5
H −3.4 6.8 0.09 1.3 6.82 0.15 2.2
Sufentanil L 3.0 5.7 0.06 1.0 5.60 0.14 2.5 0.25 50.0
M −0.2 26.7 0.44 1.7 25.5 0.56 2.2
H −1.8 53.1 1.03 1.9 52.5 1.47 2.8
Cefazolin L 8.0 6.6 0.12 1.7 6.57 0.23 3.5 1,000 100,000
M 0.4 32.1 0.39 1.2 30.9 0.34 1.1
H 0.9 101.6 1.48 1.5 104.2 1.25 1.2
Doxapram L 3.2 0.42 0.01 1.4 0.43 0.02 4.7 50 4,500
M 3.0 2.15 0.04 1.9 2.22 0.02 0.9
H −1.2 3.46 0.06 1.8 3.57 0.05 1.4
Keto‐doxapram L −4.8 0.16 0.00 1.5 0.18 0.01 5.7 50 5,000
M 3.2 0.88 0.02 2.1 0.77 0.02 2.6
H 1.7 3.43 0.08 2.4 3.43 0.12 3.5
QC, Quality control; L, low; M, medium; H, high; SD, standard deviation; RSD, relative standard deviation; ULOQ, upper limit of quantification.
TABLE 5 Matrix effect, recovery and process efficiency
Analyte
Matrix effect,
mean (%)
Recovery,
mean (%)
Process efficiency,
mean (%)
Fentanyl 113.3 102.2 115.9
Sufentanil 108.8 93.5 101.7
Cefazolin 108.0 90.1 97.4
Doxapram 111.3 92.5 102.9
Keto‐doxapram 99.9 99.2 99.1
6 of 8 FLINT ET AL.volume of 50 μL human plasma and short run time of 5.0min perfectly
met the objectives. We were able to analyze one plasma sample to
simultaneously quantify multiple drugs that were part of one treat-
ment, and combine samples with different drugs to be measured in
one assay run.
Previously reported methods for quantification of these analytes
concerned one of these analytes (with or without their metabolites)
per assay or in a combination with other drugs. These combinations
mostly concerned multiple drugs from the same drug class, i.e.
sufentanil or fentanyl with other analgosedatives by Nosseir et al.
(2014) and Fernandez Mdel et al. (2013), or cefazolin with beta‐
lactams by Carlier et al. (2012) and Kirziazopoulos et al. (2017). Our
assay concerned four drugs from three different anatomical therapeu-
tic chemical classes: fentanyl and sufentanil as nervous system drugs;
cefazolin as an anti‐infective drug; and doxapram as a respiratory drug.
Herewith, our assay enables the quantification of four drugs in one
sample simultaneously following one sample injection. This may be
valuable for TDM as well as for research, concerning patients using a
combination of these drugs as part of a particular treatment protocol.
The burden to the patient may be reduced compared with a separate
assay per drug, which is especially important concerning vulnerable
(preterm) infants. Furthermore, samples with different drugs may be
combined in one single run, which may improve the efficiency of the
laboratory process.
In general, for all analytes, our assay performed better than or
comparable to prior reported assays, even in comparison with assays
measuring only a single analyte, which makes it easier to achieve good
performance on run time, required sample volume and matrix effects(Aranda et al., 1988; Carlier et al., 2012; Clavijo et al., 2011; Fernandez
Mdel et al., 2013; Hisada et al., 2013; Kiriazopoulos et al., 2017;
LeGatt et al., 1986; Lillico et al., 2016; Mahlke et al., 2014; Nichol
et al., 1980; Nosseir et al., 2014; Palleschi et al., 2003; Parker et al.,
2016; Robson & Prescott, 1977; Saari et al., 2012; Suzuki et al.,
2017). Furthermore, most assays use a different drug as an internal
standard, whereas we used a deuterated form of fentanyl, which
shows better comparable behavior to the analytes that are measured
than using a different drug. Next, our sample preparation consisted
of a simple one‐step protein precipitation method, whereas in most
studies solid‐phase extraction is prescribed, or a liquid–liquid extrac-
tion with an evaporation and/or ultrafiltration step, or other additional
steps.
For sufentanil, other reported assays required more plasma vol-
ume and a more complex sample preparation compared with our assay
(Nosseir et al., 2014; Palleschi et al., 2003; Saari et al., 2012).
Concerning doxapram, four of the five reported assays date from the
1990s (Aranda et al., 1988; LeGatt et al., 1986; Nichol et al., 1980;
Robson & Prescott, 1977) and are inferior to our assay with respect
to the use of a different drug for internal standard, sample preparation
which requires an evaporation step, higher LLOQ, larger sample vol-
ume required, a longer run time and two assays not being able to mea-
sure keto‐doxapram. The recently published assay by Suzuki et al.
(2017) required only a 25 μL plasma volume compared with our
50 μL, and an LLOQ for doxapram of 20 μg L −1 compared with our
50 μg L−1. On the other hand, Suzuki et al. needed a 12min run time
and used propranolol as an internal standard, where we needed a
5min run time and used deuterated fentanyl, and our sample prepara-
tion required fewer operational steps. Regarding cefazolin, multiple
assays have been reported with comparable performance (Carlier
et al., 2012; Kiriazopoulos et al., 2017; Lillico et al., 2016; Parker
et al., 2016). The reported fentanyl assays required larger sample vol-
umes except for Hisada et al. (2013), who needed only 20 μL and
reached a lower LLOQ of 0.05 μg L−1 compared with our 0.1 μg L −1.
Except for cefazolin and keto‐doxapram, the stability of all
analytes was good, which means they were stable for at least 120 h
when stored in the autosampler at 15°C. Cefazolin was only stable
FLINT ET AL. 7 of 8for 72 h and keto‐doxapram only for 48 h at 15°C. Suzuki et al. (2017)
tested the stability of keto‐doxapram for 48 h at 10°C for autosampler
conditions and also found it to be stable for that time. Stability during
three cycles of freezing and thawing, and freezer stability studies of
the analytes in the matrix are not presented because they were
already carried out in previous published papers and do not depend
on the analytical method. No relevant effects of freezing and thawing
were found for all analytes, together with good stability at −20°C for
4weeks (Clavijo et al., 2011; Kiriazopoulos et al., 2017; Mahlke
et al., 2014; Nosseir et al., 2014; Palleschi et al., 2003; Parker et al.,
2016; Saari et al., 2012; Suzuki et al., 2017).
Our assay fulfilled the desired criteria for accuracy, repeatability
and reproducibility. Furthermore, for all analytes a good recovery
was achieved and matrix effects were measured. These indicated the
absence of interferences by matrix compounds, stable isotope‐labeled
internal standard and co‐eluting compounds that may cause ion sup-
pression and ion enhancement.
The ranges for linearity for all analytes were perfectly suitable for
clinical pharmacology research, as well as for possible TDM purposes.
The assay was successfully validated for clinical practice and research
purposes for fentanyl and doxapram. Fentanyl was quantified in 370
plasma samples from 92 preterm infants, and doxapram and keto‐
doxapram in 248 plasma samples from 65 preterms. The considerably
high proportion of samples below the LLOQ (21% for fentanyl, 12%
for doxapram, 13% for keto‐doxapram) was due to the objective of
the study of investigating drug pharmacokinetics. Therefore, to esti-
mate the clearance of the investigated drugs, opportunistic sample
collection was allowed up to and beyond the time at which the plasma
concentrations decreased below the LLOQ. All samples collected dur-
ing continuous administration of both drugs were all above the LLOQ
for all three analytes, and only above ULOQ for three doxapram sam-
ples shortly after a bolus administration. In conclusion, the assay per-
formed well for samples in clinical practice. Furthermore,
investigation is currently in progress in which this method has been
applied to several pharmacokinetic studies in preterm infants up to
elderly patients.
Despite the good performance, our assay has certain limitations.
First, the stability of cefazolin and keto‐doxapram did not reach the
desired 120 h at 15°C in the autosampler. However, as performance
of the assay was finished within 48 h, this did not create a problem
in practice. Second, although the plasma volume of 50 μL for
performing the assay was small, this may be too much for some pre-
term infants, and for quantification of multiple drugs requiring the
use of different assays. Third, the LLOQ of certain analytes in our
assay was higher than some reported assays quantifying a single ana-
lyte. This is due to our goal of quantifying multiple analytes in one run
simultaneously, which makes it more difficult to achieve maximal per-
formance for all analytes. Nevertheless, the LLOQs of our assay all
meet the clinically required limits of quantification. Fourth, the assay
did not include inactive metabolites as these are not relevant for clin-
ical practice. Therefore, only keto‐doxapram was included being the
active metabolite of doxapram.
It has been suggested that TDM should be implemented as a sup-
portive tool for analgosedation for fentanyl and sufentanil, which may
help physicians increase patient comfort regarding intra‐ and inter‐operative interventions (Nosseir et al., 2014). The value of TDM has
also been suggested for beta‐lactam antibiotics (Huttner, Harbarth,
Hope, Lipman, & Roberts, 2015). Quantification of doxapram and
keto‐doxapram during therapeutic dosages of doxapram may be rele-
vant to improve successful therapy even further in the treatment of
apnea of prematurity (Hayakawa et al., 1986) and for evaluation of
safety (Barbe et al., 1999).5 | CONCLUSIONS
We have developed a method for the simultaneous quantification of
fentanyl, sufentanil, cefazolin, doxapram and keto‐doxapram in 50 μL
human plasma within a run time of only 5.0min. This greatly facilitates
further research into these drugs as well as possible TDM purposes,
even in the smallest plasma volumes obtained from preterm infants.
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